Testing effectiveness (Phase 2)Active Not RecruitingNCT03322865What this trial is testingObinutuzumab in Marginal Zone LymphomaWho this might be right forMarginal Zone Lymphoma Christian Buske 56
Early research (Phase 1)UnknownNCT06279611What this trial is testingAn Evaluation of LY007 Cell Injection for r/r B-NHLWho this might be right forB-NHL Shanghai Longyao Biotechnology Inc., Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT01538472What this trial is testingY Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for LymphomaWho this might be right forLymphoma M.D. Anderson Cancer Center 40
Early research (Phase 1)Active Not RecruitingNCT05737628What this trial is testingFirst-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228Who this might be right forLymphoma Byondis B.V. 17
Early research (Phase 1)Ended earlyNCT05318963What this trial is testingTargeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell LymphomaWho this might be right forB-cell Lymphoma RecurrentB-cell Lymphoma Refractory Institute of Hematology & Blood Diseases Hospital, China 14
Testing effectiveness (Phase 2)UnknownNCT04553393What this trial is testingDecitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor BurdenWho this might be right forRefractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden Chinese PLA General Hospital 80
Early research (Phase 1)Study completedNCT03332121What this trial is testingB001 in Patients With CD20 Positive B-cell Non Hodgkin's LymphomaWho this might be right forCD20 Positive B Cell Non-Hodgkin's Lymphoma Shanghai Pharmaceuticals Holding Co., Ltd 30
Early research (Phase 1)Looking for participantsNCT06703892What this trial is testingEvaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological MalignanciesWho this might be right forDiffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma RefractoryFollicular Lymphoma ( FL)+3 more GenomeFrontier Therapeutics TW Co., Ltd. 18
Large-scale testing (Phase 3)Study completedNCT01724021What this trial is testingParticipant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aWho this might be right forDiffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma Hoffmann-La Roche 743
Not applicableUnknownNCT00400907What this trial is testingObservation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9Who this might be right forLong-term Effects Secondary to Cancer Therapy in AdultsLymphoma German High-Grade Non-Hodgkin's Lymphoma Study Group 667
Large-scale testing (Phase 3)Study completedNCT00052936What this trial is testingCombination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaWho this might be right forLymphoma German High-Grade Non-Hodgkin's Lymphoma Study Group 1,506
Not applicableNot Yet RecruitingNCT07492407What this trial is testingCD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell LymphomaWho this might be right forMZL Henan Cancer Hospital 131
Very early researchNot Yet RecruitingNCT07546630What this trial is testingNanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell LymphomaWho this might be right forRelapsed/Refractory B-Cell Lymphoma Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)Study completedNCT04696432What this trial is testingC-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaWho this might be right forNon-Hodgkin's B-cell Lymphoma Tianjin Medical University Cancer Institute and Hospital 7
Not applicableNot Yet RecruitingNCT07345741What this trial is testingClinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forR/R B-NHLRelapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) Donghua Zhang 28
Testing effectiveness (Phase 2)Study completedNCT00166439What this trial is testingTrial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins LymphomaWho this might be right forLymphoma Academic and Community Cancer Research United 50
Testing effectiveness (Phase 2)WithdrawnNCT00004039What this trial is testingCombination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV LymphomaWho this might be right forLymphoma Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)UnknownNCT02678299What this trial is testingPhase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN StudyWho this might be right forMalignant Lymphoma University of Aarhus 60
Early research (Phase 1)Active Not RecruitingNCT05797233What this trial is testingTrial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell MalignanciesWho this might be right forChronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic LeukemiaLymphoma, B-Cell National Cancer Institute (NCI) 58
Testing effectiveness (Phase 2)WithdrawnNCT00093314What this trial is testingHuMax-CD20 in Chronic Lymphocytic LeukemiaWho this might be right forChronic Lymphocytic Leukemia GlaxoSmithKline